Quinazolinone-based Anticancer Agents: Synthesis, Anti-proliferative SAR, Anti-tubulin Activity and Tubulin Co-crystal Structure

Wolfgang Dohle, Fabrice Jourdan, Gregory Menchon, Andrea Prota, Paul A. Foster, Pascoe Mannion, Ernest Hamel, Mark Thomas, Philip G Kasprzyk, Eric Ferrandis, Michel O. Steinmetz, Mathew Leese, Barry Potter

Research output: Contribution to journalArticle

Abstract

Quinazolinone-based anti-cancer agents were designed, decorated with functional groups from a 2-methoxyestradiol-based microtubule disruptor series, incorporating the aryl sulfamate motif of steroid sulfatase (STS) inhibitors. The steroidal AB-ring system was mimicked, favoring conformations with an N-2 substituent occupying D-ring space. Evaluation against breast and prostate tumor cell lines identified 7b with DU-145 anti-proliferative activity (GI50 300 nM). A preliminary structure-activity relationship afforded compounds (e.g. 7j GI50 50 nM) with activity exceeding that of the parent. Both 7b and 7j inhibit tubulin assembly in vitro and colchicine binding and 7j was successfully co-crystallized with the αβ-tubulin heterodimer as the first of its class, its sulfamate group interacting positively at the colchicine binding site. Microtubule destabilization by 7j likely prevents the curved-to-straight conformational transition. Quinazolinone sulfamates surprisingly showed weak STS inhibition. Preliminary in vivo studies in a multiple myeloma xenograft model for 7b showed oral activity, confirming the promise of this template.
Original languageEnglish
Number of pages49
JournalJournal of Medicinal Chemistry
Early online date11 Dec 2017
Publication statusUnpublished - 2018

Fingerprint

Quinazolinones
Tubulin
Steryl-Sulfatase
Antineoplastic Agents
Colchicine
Microtubules
Structure-Activity Relationship
Tumor Cell Line
Multiple Myeloma
Heterografts
Prostate
Binding Sites
Breast Neoplasms
sulfamic acid
Neoplasms

Cite this

Dohle, W., Jourdan, F., Menchon, G., Prota, A., Foster, P. A., Mannion, P., ... Potter, B. (2018). Quinazolinone-based Anticancer Agents: Synthesis, Anti-proliferative SAR, Anti-tubulin Activity and Tubulin Co-crystal Structure. Unpublished.

Quinazolinone-based Anticancer Agents: Synthesis, Anti-proliferative SAR, Anti-tubulin Activity and Tubulin Co-crystal Structure. / Dohle, Wolfgang; Jourdan, Fabrice; Menchon, Gregory; Prota, Andrea; Foster, Paul A.; Mannion, Pascoe; Hamel, Ernest; Thomas, Mark; Kasprzyk, Philip G; Ferrandis, Eric; Steinmetz, Michel O.; Leese, Mathew; Potter, Barry.

In: Journal of Medicinal Chemistry, 2018.

Research output: Contribution to journalArticle

Dohle, W, Jourdan, F, Menchon, G, Prota, A, Foster, PA, Mannion, P, Hamel, E, Thomas, M, Kasprzyk, PG, Ferrandis, E, Steinmetz, MO, Leese, M & Potter, B 2018, 'Quinazolinone-based Anticancer Agents: Synthesis, Anti-proliferative SAR, Anti-tubulin Activity and Tubulin Co-crystal Structure', Journal of Medicinal Chemistry.
Dohle, Wolfgang ; Jourdan, Fabrice ; Menchon, Gregory ; Prota, Andrea ; Foster, Paul A. ; Mannion, Pascoe ; Hamel, Ernest ; Thomas, Mark ; Kasprzyk, Philip G ; Ferrandis, Eric ; Steinmetz, Michel O. ; Leese, Mathew ; Potter, Barry. / Quinazolinone-based Anticancer Agents: Synthesis, Anti-proliferative SAR, Anti-tubulin Activity and Tubulin Co-crystal Structure. In: Journal of Medicinal Chemistry. 2018.
@article{2f2c4630381b40a59f31afc978a4e259,
title = "Quinazolinone-based Anticancer Agents: Synthesis, Anti-proliferative SAR, Anti-tubulin Activity and Tubulin Co-crystal Structure",
abstract = "Quinazolinone-based anti-cancer agents were designed, decorated with functional groups from a 2-methoxyestradiol-based microtubule disruptor series, incorporating the aryl sulfamate motif of steroid sulfatase (STS) inhibitors. The steroidal AB-ring system was mimicked, favoring conformations with an N-2 substituent occupying D-ring space. Evaluation against breast and prostate tumor cell lines identified 7b with DU-145 anti-proliferative activity (GI50 300 nM). A preliminary structure-activity relationship afforded compounds (e.g. 7j GI50 50 nM) with activity exceeding that of the parent. Both 7b and 7j inhibit tubulin assembly in vitro and colchicine binding and 7j was successfully co-crystallized with the αβ-tubulin heterodimer as the first of its class, its sulfamate group interacting positively at the colchicine binding site. Microtubule destabilization by 7j likely prevents the curved-to-straight conformational transition. Quinazolinone sulfamates surprisingly showed weak STS inhibition. Preliminary in vivo studies in a multiple myeloma xenograft model for 7b showed oral activity, confirming the promise of this template.",
author = "Wolfgang Dohle and Fabrice Jourdan and Gregory Menchon and Andrea Prota and Foster, {Paul A.} and Pascoe Mannion and Ernest Hamel and Mark Thomas and Kasprzyk, {Philip G} and Eric Ferrandis and Steinmetz, {Michel O.} and Mathew Leese and Barry Potter",
year = "2018",
language = "English",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",

}

TY - JOUR

T1 - Quinazolinone-based Anticancer Agents: Synthesis, Anti-proliferative SAR, Anti-tubulin Activity and Tubulin Co-crystal Structure

AU - Dohle, Wolfgang

AU - Jourdan, Fabrice

AU - Menchon, Gregory

AU - Prota, Andrea

AU - Foster, Paul A.

AU - Mannion, Pascoe

AU - Hamel, Ernest

AU - Thomas, Mark

AU - Kasprzyk, Philip G

AU - Ferrandis, Eric

AU - Steinmetz, Michel O.

AU - Leese, Mathew

AU - Potter, Barry

PY - 2018

Y1 - 2018

N2 - Quinazolinone-based anti-cancer agents were designed, decorated with functional groups from a 2-methoxyestradiol-based microtubule disruptor series, incorporating the aryl sulfamate motif of steroid sulfatase (STS) inhibitors. The steroidal AB-ring system was mimicked, favoring conformations with an N-2 substituent occupying D-ring space. Evaluation against breast and prostate tumor cell lines identified 7b with DU-145 anti-proliferative activity (GI50 300 nM). A preliminary structure-activity relationship afforded compounds (e.g. 7j GI50 50 nM) with activity exceeding that of the parent. Both 7b and 7j inhibit tubulin assembly in vitro and colchicine binding and 7j was successfully co-crystallized with the αβ-tubulin heterodimer as the first of its class, its sulfamate group interacting positively at the colchicine binding site. Microtubule destabilization by 7j likely prevents the curved-to-straight conformational transition. Quinazolinone sulfamates surprisingly showed weak STS inhibition. Preliminary in vivo studies in a multiple myeloma xenograft model for 7b showed oral activity, confirming the promise of this template.

AB - Quinazolinone-based anti-cancer agents were designed, decorated with functional groups from a 2-methoxyestradiol-based microtubule disruptor series, incorporating the aryl sulfamate motif of steroid sulfatase (STS) inhibitors. The steroidal AB-ring system was mimicked, favoring conformations with an N-2 substituent occupying D-ring space. Evaluation against breast and prostate tumor cell lines identified 7b with DU-145 anti-proliferative activity (GI50 300 nM). A preliminary structure-activity relationship afforded compounds (e.g. 7j GI50 50 nM) with activity exceeding that of the parent. Both 7b and 7j inhibit tubulin assembly in vitro and colchicine binding and 7j was successfully co-crystallized with the αβ-tubulin heterodimer as the first of its class, its sulfamate group interacting positively at the colchicine binding site. Microtubule destabilization by 7j likely prevents the curved-to-straight conformational transition. Quinazolinone sulfamates surprisingly showed weak STS inhibition. Preliminary in vivo studies in a multiple myeloma xenograft model for 7b showed oral activity, confirming the promise of this template.

M3 - Article

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

ER -